BRAF mutation

From Libre Pathology
Revision as of 18:15, 23 January 2019 by Michael (talk | contribs) (create)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

BRAF mutation is a common genetic change in cancer.

General

  • BRAF inhibitors (e.g. vemurafenib) is used to treat BRAF mutation positive tumours.[1]
    • BRAF mutations in ~ 50% of melanomas; respond to BRAF inhibitors.
    • BRAF mutations in ~ 10% of colorectal tumours.
      • Poor prognosticator, poor response to chemotherapy, typically right sided tumours.
    • BRAF mutations in ~45-50% of papillary thyroid carcinoma.
    • BRAF mutations in ~3% of lung adenocarcinomas.

References

  1. Cheng, L.; Lopez-Beltran, A.; Massari, F.; MacLennan, GT.; Montironi, R. (01 2018). "Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine.". Mod Pathol 31 (1): 24-38. doi:10.1038/modpathol.2017.104. PMID 29148538.